Many U.S.-traded global stocks have the potential to more than double over the next 12 months, based on average analyst price targets. CNBC Pro screens U.S.-listed stocks of companies headquartered overseas that are covered by 10 or more analysts. The table below lists 11 stocks that analysts believe have more than 100% upside potential in local currency terms over the next 12 months. Investors should note that these stocks are subject to risk from foreign exchange fluctuations. Among stocks screened using FactSet data, Canada's Patriot Battery Metals has the best upside potential, rising 259% over the next 12 months, although analysts view the hard-rock lithium explorer as a risk bet. Lithium, currently produced from hard rock or brine deposits, has become a sought-after metal for the electric vehicle industry. Although the company is primarily listed on the Toronto Stock Exchange, its shares also trade on U.S. exchanges. PMETF 1Y Line The company recently unveiled plans for its Shaakichiuwaanaan lithium project in James Bay, Quebec. Desjardins analysts led by Frederic Tremblay said in a note to clients on August 22: “We believe the (preliminary economic assessment) shows attractive project economics and strengthens PMET’s emergence as a major global hard rock lithium producer. Likewise, Canaccord Genuity analysts Katie Lachapelle and Meaghan Charlebois have a Speculative Buy rating on the stock, with a price target of C$13. Valneva, based in France, ranks second on the list at C$213. %. It is one of the few remaining independent vaccine companies and has successfully developed two in-house vaccines, and it is also leading the development of a Lyme disease vaccine it has approved for marketing, analysts said. Will be strong and royalties could grow long-term if Lyme disease vaccine launches successfully Results continue to highlight the vaccine's potential, demonstrating a robust immune response against Lyme disease as part of a booster regimen, with the trial expected to be completed in July 2024. The price target is 9 euros ($9.94) per share, indicating 201% upside potential for the stock. Valneva is listed on the Paris Stock Exchange and also trades on the U.S. exchange VALN 1Y. Likewise, Guggenheim Securities. Analysts are also optimistic about the stock's performance over the next 12 months. Guggenheim analysts led by Evan Wang said in a report: “We expect VALN's operating margin to expand to around 40% over time ( Factoring in rising Lyme royalty contributions) and assuming a post-(net operating loss) tax rate of 21%, the analysts added: “While we believe VALN's late-stage clinical program risk has been significantly reduced, the Several clinical, manufacturing and commercialization risks remain before and after licensure. “